Effects of Cardiopulmonary Support With a Novel Pediatric Pump-Lung in a 30-Day Ovine Animal Model.
The scarcity of donor organs has led to the development of devices that provide optimal long-term respiratory or cardiopulmonary support to bridge recipients as they wait for lung and/or heart transplantation. This study was designed to evaluate the 30-day in vivo performance of the newly developed pediatric pump-lung (PediPL) for cardiopulmonary support using a juvenile sheep model. The PediPL device was placed surgically between the right atrium and descending aorta in eight sheep (25.4-31.2 kg) and evaluated for 30 days. Anticoagulation was maintained with continuous heparin infusion (activated clotting time 150-200 s). The flow rate was measured continually, and gas transfer was measured daily. Plasma free hemoglobin, platelet activation, hematologic data, and blood biochemistry were assessed twice a week. Sheep were euthanized after 30 days. The explanted devices were examined for gross thrombosis. Six sheep survived for 30-32 days. During the study, the oxygen transfer rate of the devices was 54.9 ± 13.2 mL/min at a mean flow rate of 1.14 ± 0.46 L/min with blood oxygen saturation of 95.4% ± 1.7%. Plasma free hemoglobin was 8.2 ± 3.7 mg/dL. Platelet activation was 5.35 ± 2.65%. The animals had normal organ chemistries except for surgery-related transient alterations in kidney and liver function. Although we found some scattered thrombi on the membrane surfaces of some explanted devices during the necropsy, the device function and performance did not degrade. The PediPL device was capable of providing cardiopulmonary support with long-term reliability and good biocompatibility over the 30-day duration and offers the potential option for bridging pediatric patients with end-stage heart or lung disease to heart and/or lung transplantation.
Department of Surgery, Artificial Organs Laboratory, University of Maryland School of Medicine, Baltimore, MD, USA.
Yang
Y
Liu
Department of Surgery, Artificial Organs Laboratory, University of Maryland School of Medicine, Baltimore, MD, USA.
Pablo G
PG
Sanchez
Department of Surgery, Artificial Organs Laboratory, University of Maryland School of Medicine, Baltimore, MD, USA.
Xufeng
X
Wei
Department of Surgery, Artificial Organs Laboratory, University of Maryland School of Medicine, Baltimore, MD, USA.
Amelia C
AC
Watkins
Department of Surgery, Artificial Organs Laboratory, University of Maryland School of Medicine, Baltimore, MD, USA.
Shuqiong
S
Niu
Department of Surgery, Artificial Organs Laboratory, University of Maryland School of Medicine, Baltimore, MD, USA.
Zhongjun J
ZJ
Wu
Department of Surgery, Artificial Organs Laboratory, University of Maryland School of Medicine, Baltimore, MD, USA.
Bartley P
BP
Griffith
D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage; D001672:Biocompatible Materials; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects; D004867:Equipment Design; D004868:Equipment Failure; D006355:Heart-Lung Machine / Q000009:adverse effects; D006454:Hemoglobins / Q000378:metabolism; D006493:Heparin / Q000008:administration & dosage; D007770:L-Lactate Dehydrogenase / Q000097:blood; D023421:Models, Animal; D010100:Oxygen / Q000097:blood; D015539:Platelet Activation; D012756:Sheep; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D013997:Time Factors
D000925:Anticoagulants; D001672:Biocompatible Materials; D015415:Biomarkers; D006454:Hemoglobins; D006493:Heparin; D007770:L-Lactate Dehydrogenase; D010100:Oxygen
Artificial pump-lung; Cardiopulmonary support; Heart transplantation; Lung transplantation; Pediatric